Galera Therapeutics, Inc. (NasdaqGM:GRTX) has engaged Stifel, Nicolaus & Company, Inc. to assist in reviewing strategic alternatives for the Company and its portfolio of dismutase mimetics with the goal of maximizing value for its shareholders. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. If the Company is unable to undertake any strategic alternative, it may be required to cease operations altogether.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0832 USD | -7.56% | -15.96% | -42.78% |
Jun. 07 | Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer | CI |
Jun. 06 | Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-42.78% | 4.53M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.57B | |
-18.26% | 20.82B | |
-18.47% | 16.19B | |
-42.36% | 16.17B | |
-14.23% | 16.3B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics Announces Review of Strategic Alternatives